Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supp
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
08:41am, Friday, 14'th Mar 2025
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
08:00am, Tuesday, 11'th Mar 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 20
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
07:00am, Wednesday, 05'th Mar 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company'
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
07:00am, Tuesday, 25'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. Th
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
10:01am, Friday, 14'th Feb 2025
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.
Alnylam: Waiting For Regulatory Updates In March
05:01pm, Thursday, 13'th Feb 2025
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchi
Alnylam Delivers a Big Q4 Earnings Beat
01:17pm, Thursday, 13'th Feb 2025
Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) ca
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript
12:31pm, Thursday, 13'th Feb 2025
Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
10:36am, Thursday, 13'th Feb 2025
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stre
Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates
10:16am, Thursday, 13'th Feb 2025
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to loss of $1.10 per share a year a
ILMN vs. ALNY: Which Stock Is the Better Value Option?
12:40pm, Tuesday, 11'th Feb 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value inves
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
02:46pm, Monday, 10'th Feb 2025
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:21am, Monday, 10'th Feb 2025
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:05am, Thursday, 06'th Feb 2025
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
